Researchers at CRISPR Therapeutics compare three homology-independent off-target assessment methods– GUIDE-seq, CIRCLE-seq and SITE-seq–and infer all three methods are competent means of nominating off-target sites, validating CRISPR-Cas9 as a platform for the development of clinical therapeutics.
Scroll Up
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our privacy policy.